HUP0400465A2 - Kortikotropin-feloldó faktor (CRF) receptor antagonista biciklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Kortikotropin-feloldó faktor (CRF) receptor antagonista biciklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0400465A2 HUP0400465A2 HU0400465A HUP0400465A HUP0400465A2 HU P0400465 A2 HUP0400465 A2 HU P0400465A2 HU 0400465 A HU0400465 A HU 0400465A HU P0400465 A HUP0400465 A HU P0400465A HU P0400465 A2 HUP0400465 A2 HU P0400465A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- cycloalkyl
- Prior art date
Links
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 title abstract 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title abstract 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 title abstract 3
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- -1 nitro- Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A találmány (I) általános képletű vegyületekre - amelynek képletében Raril- vagy heteroarilcsoport, amelyek mindegyike adott esetben akövetkező csoportból kiválasztott 1-4 szubsztituenst hordozhat:halogénatom, alkil-, alkoxi-, halogén-alkil-, alkenil-, alkinil-,halogén-alkoxi-, -C(O)R5, nitro, -NR6R7, ciano- és/vagy -R8-csoport;R1 hidrogénatom, alkil-, alkenil-, alkinil-, halogén-alkil-, halogén-alkoxi-csoport, halogénatom, -NR6R7 vagy cianocsoport; R2hidrogénatom, cikloalkil- vagy -R9 csoport; R3 cikloalkil- vagy -R9csoport; vagy R2 és R3 a nitrogénatommal együtt egy 5-14 tagúheterociklusos csoportot képez, ami adott esetben 1-3 -R10 általánosképletű csoporttal szubsztituált lehet; R4 hidrogén-, halogénatom,alkil- vagy halogén-alkil-csoport; R5 alkil-, -OR6 vagy -NR6R7csoport; R6 és R7 hidrogénatom vagy alkilcsoport; R8 telített vagy 1-3kettős kötést tartalmazó, adott esetben egy vagy több -R11 általánosképletű csoporttal szubsztituált 5-6 tagú heterociklusos csoport; R9alkilcsoport, ami adott esetben a következő csoportból kiválasztottegy vagy több szubsztituenst hordozhat: cikloalkil-, alkoxi-, halogén-alkoxi-, hidroxi- és/vagy halogén-alkil-csoport; Rl0 -R8, cikloalkil-,alkil-, alkoxi-, halogén-alkil-, alkenil-, alkinil-, halogén-alkoxi-,hidroxicsoport, halogénatom, nitro-, ciano-, -C(O)NR6R7 csoport, vagyadott esetben 1-4 -R11 általános képletű csoporttal szubsztituáltfenilcsoport; R11 cikloalkil-, alkil-, alkoxi-, halogén-alkil-,alkenil-, alkinil-, halogén-alkoxi-, hidroxicsoport, halogénatom,nitro-, ciano- vagy -C(O)NR6R7 csoport; X szén- vagy nitrogénatom; ésn értéke 1 vagy 2 és sztereoizomereikre, prodrugjaikra, valamintgyógyászatilag elfogadható sóikra és szolvátjaikra, továbbá avegyületek előállítási eljárásaira, a vegyületeket tartalmazógyógyszerkészítményekre és a vegyületek kortikotropin-releasing faktor(CRF) által mediált állapotok kezelésében történő felhasználásáravonatkozik. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117396.2A GB0117396D0 (en) | 2001-07-17 | 2001-07-17 | Chemical compounds |
| PCT/EP2002/007865 WO2003008412A2 (en) | 2001-07-17 | 2002-07-15 | Hetero-bicyclic crf antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0400465A2 true HUP0400465A2 (hu) | 2005-01-28 |
Family
ID=9918655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400465A HUP0400465A2 (hu) | 2001-07-17 | 2002-07-15 | Kortikotropin-feloldó faktor (CRF) receptor antagonista biciklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7253284B2 (hu) |
| EP (2) | EP1425280B1 (hu) |
| JP (1) | JP4459616B2 (hu) |
| KR (2) | KR100961287B1 (hu) |
| CN (1) | CN100447141C (hu) |
| AT (2) | ATE338042T1 (hu) |
| AU (1) | AU2002328899B2 (hu) |
| BR (1) | BR0211171A (hu) |
| CA (1) | CA2451530A1 (hu) |
| CO (1) | CO5550437A2 (hu) |
| CY (1) | CY1105780T1 (hu) |
| DE (2) | DE60214401T2 (hu) |
| DK (1) | DK1425280T3 (hu) |
| ES (2) | ES2271327T3 (hu) |
| GB (2) | GB0117396D0 (hu) |
| HK (1) | HK1066535A1 (hu) |
| HU (1) | HUP0400465A2 (hu) |
| IL (1) | IL159254A0 (hu) |
| MX (1) | MXPA04000494A (hu) |
| NO (1) | NO20040206L (hu) |
| NZ (1) | NZ530043A (hu) |
| PL (1) | PL368053A1 (hu) |
| PT (1) | PT1425280E (hu) |
| RU (1) | RU2310655C2 (hu) |
| SI (1) | SI1425280T1 (hu) |
| WO (1) | WO2003008412A2 (hu) |
| ZA (1) | ZA200309708B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395591B1 (en) * | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| DE602004005960T2 (de) * | 2003-01-16 | 2008-01-17 | Sb Pharmco Puerto Rico Inc. | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0308208D0 (en) * | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7737154B2 (en) | 2003-12-22 | 2010-06-15 | Smithkline Beecham (Cork) Limited | CRF receptor antagonists and methods relating thereto |
| EP1802621B1 (en) * | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US8088779B2 (en) | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| US8513420B2 (en) | 2007-03-19 | 2013-08-20 | Monika Mazik | Amino-naphthyridine derivatives |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| WO2009008552A1 (en) * | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JP6199991B2 (ja) | 2013-01-18 | 2017-09-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ３置換ピラゾール及びｄｌｋ阻害剤としての使用 |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169857A (en) | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| GB2248618B (en) | 1988-06-17 | 1993-01-06 | Wyeth John & Brother Ltd | Process for preparing pyridine derivatives |
| CA2022408A1 (en) | 1989-08-31 | 1991-03-01 | Michael P. Bodman | Process for preparing pyridine carboxylic acid derivatives |
| DK0495982T3 (da) | 1989-10-11 | 1996-07-01 | Teijin Ltd | Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel |
| DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
| AU665184B2 (en) | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
| US5246944A (en) * | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| KR960704855A (ko) | 1993-10-12 | 1996-10-09 | 돈 엠. 커. | 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof) |
| TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| CA2192820C (en) | 1994-06-16 | 2000-11-28 | Yuhpyng L. Chen | Pyrazolo and pyrrolopyridines |
| EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| AU738304B2 (en) | 1995-10-13 | 2001-09-13 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands |
| US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| EP0920429B1 (en) | 1996-08-06 | 2003-02-19 | Pfizer Inc. | Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| EA002769B1 (ru) * | 1996-08-28 | 2002-08-29 | Пфайзер Инк. | Замещенные 6,5-гетеробициклические производные |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法 |
| ATE296825T1 (de) | 1997-08-05 | 2005-06-15 | Pfizer Prod Inc | 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten |
| WO1999051599A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| JPH11335376A (ja) | 1998-05-25 | 1999-12-07 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| JP2000086663A (ja) | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| CA2365401A1 (en) | 1999-03-11 | 2000-10-05 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| EP1165542B1 (en) | 1999-03-29 | 2003-08-20 | Neurogen Corporation | 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| JP2003510327A (ja) | 1999-09-30 | 2003-03-18 | ニューロジェン・コーポレーション | 特定のアルキレンジアミンで置換された複素環 |
| US6525067B1 (en) | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
| EP1263732A1 (en) | 2000-01-18 | 2002-12-11 | Pfizer Products Inc. | Corticotropin releasing factor antagonists |
| AR028782A1 (es) | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| WO2002019975A1 (fr) | 2000-09-05 | 2002-03-14 | Taisho Pharmaceutical Co., Ltd. | Stimulants de la croissance des cheveux |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| EP1383747B1 (en) | 2001-04-30 | 2008-02-20 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| EP1395591B1 (en) | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE602004005960T2 (de) | 2003-01-16 | 2008-01-17 | Sb Pharmco Puerto Rico Inc. | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten |
| TW200418830A (en) | 2003-02-14 | 2004-10-01 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-07-17 GB GBGB0117396.2A patent/GB0117396D0/en not_active Ceased
-
2002
- 2002-07-11 GB GB0216041A patent/GB2378702A/en not_active Withdrawn
- 2002-07-15 EP EP02764696A patent/EP1425280B1/en not_active Expired - Lifetime
- 2002-07-15 AU AU2002328899A patent/AU2002328899B2/en not_active Ceased
- 2002-07-15 NZ NZ530043A patent/NZ530043A/xx unknown
- 2002-07-15 BR BR0211171-3A patent/BR0211171A/pt not_active IP Right Cessation
- 2002-07-15 US US10/483,792 patent/US7253284B2/en not_active Expired - Fee Related
- 2002-07-15 CA CA002451530A patent/CA2451530A1/en not_active Abandoned
- 2002-07-15 MX MXPA04000494A patent/MXPA04000494A/es active IP Right Grant
- 2002-07-15 RU RU2004104349/04A patent/RU2310655C2/ru not_active IP Right Cessation
- 2002-07-15 HU HU0400465A patent/HUP0400465A2/hu unknown
- 2002-07-15 AT AT02764696T patent/ATE338042T1/de not_active IP Right Cessation
- 2002-07-15 ES ES02764696T patent/ES2271327T3/es not_active Expired - Lifetime
- 2002-07-15 PT PT02764696T patent/PT1425280E/pt unknown
- 2002-07-15 JP JP2003513971A patent/JP4459616B2/ja not_active Expired - Fee Related
- 2002-07-15 KR KR1020047000696A patent/KR100961287B1/ko not_active IP Right Cessation
- 2002-07-15 KR KR1020097020632A patent/KR20090110386A/ko not_active Application Discontinuation
- 2002-07-15 DE DE60214401T patent/DE60214401T2/de not_active Expired - Lifetime
- 2002-07-15 SI SI200230419T patent/SI1425280T1/sl unknown
- 2002-07-15 WO PCT/EP2002/007865 patent/WO2003008412A2/en active Application Filing
- 2002-07-15 CN CNB02813866XA patent/CN100447141C/zh not_active Expired - Fee Related
- 2002-07-15 IL IL15925402A patent/IL159254A0/xx unknown
- 2002-07-15 ES ES06076176T patent/ES2342417T3/es not_active Expired - Lifetime
- 2002-07-15 AT AT06076176T patent/ATE461197T1/de not_active IP Right Cessation
- 2002-07-15 EP EP06076176A patent/EP1695974B1/en not_active Expired - Lifetime
- 2002-07-15 DE DE60235729T patent/DE60235729D1/de not_active Expired - Lifetime
- 2002-07-15 PL PL02368053A patent/PL368053A1/xx unknown
- 2002-07-15 DK DK02764696T patent/DK1425280T3/da active
-
2003
- 2003-12-15 ZA ZA200309708A patent/ZA200309708B/xx unknown
-
2004
- 2004-01-16 NO NO20040206A patent/NO20040206L/no not_active Application Discontinuation
- 2004-01-16 CO CO04002410A patent/CO5550437A2/es not_active Application Discontinuation
- 2004-11-30 HK HK04109443A patent/HK1066535A1/xx not_active IP Right Cessation
-
2006
- 2006-11-14 CY CY20061101650T patent/CY1105780T1/el unknown
-
2007
- 2007-05-16 US US11/749,433 patent/US20070219232A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400465A2 (hu) | Kortikotropin-feloldó faktor (CRF) receptor antagonista biciklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MY129796A (en) | Novel anti-inflammatory androstane derivatives | |
| TW200508232A (en) | Bicyclic derivatives, their preparation, pharmaceutical compositions containing them and their use in therapy | |
| HK1069169A1 (en) | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| TN2009000109A1 (en) | New benzamide derivatives as brad ykinin antagonists | |
| DK1483251T3 (da) | C3-cyano-epothilon-derivater | |
| TW200512201A (en) | New heterocyclic amides | |
| ATE359782T1 (de) | Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten | |
| MX2009013775A (es) | Sustituto novedoso de piperidones sustituidas como inductor de hsp. | |
| ATE397609T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
| TNSN02096A1 (en) | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| HUP0400460A2 (hu) | Kortikotropin-feloldó faktor (CRF) receptor antagonista triciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| WO2008031771A3 (en) | 3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |